The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1709
ISSUE1709
August 19, 2024
Donanemab (Kisunla) for Alzheimer's Disease
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Donanemab (Kisunla) for Alzheimer's Disease
August 19, 2024 (Issue: 1709)
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be started
in patients with mild cognitive...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.